Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
(S)-5-Bromonaproxen
271
CHF
CHF 271.00
In stock
CDX-N0272-M05050 mgCHF 271.00
CDX-N0272-M250250 mgCHF 638.00
NEW
| Product Details | |
|---|---|
| Synonyms | Naproxen Impurity C; (αS)-5-Bromo-6-methoxy-α-methyl-2-naphthaleneacetic acid; (2S)-2-(5-Bromo-6-methoxy-2-naphthyl)propionic acid |
| Product Type | Chemical |
| Properties | |
| Formula | C14H13BrO3 |
| MW | 309.16 |
| CAS | 84236-26-0 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥97% (NMR) |
| Appearance | Off-white crystalline powder. |
| Solubility | Soluble in chloroform. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | JZRWXNBIQCMXSU-QMMMGPOBSA-N |
| Smiles | BrC1=C(C=CC([C@@H](C(O)=O)C)=C2)C2=CC=C1OC |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +20°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
(S)-5-Bromonaproxen (Naproxen Impurity C) is a brominated metabolite (most probably through reaction with water) from Naproxen which is a non-steroidal anti-inflammatory drug (NSAID) used to in the treatment of pain, menstrual cramps, inflammatory diseases such as rheumatoid arthritis, gout and fever. Ibuprofen is an anti-inflammatory COX inhibitor. This product can be used as a secondary analytical reference standard or as an organic building block and intermediate for synthesis, especially targeted bromination.
Product References
(1) C. Giordano, et al.; Tetrahedr. 45, 4243 (1989) | (2) K. Solakyildirim, et al.; Magn. Reson. Chem. 52, 310 (2014) | (3) Y. Satkar, et al.; RSC Adv. 8, 17806 (2018)